Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
07:00am, Thursday, 05'th Feb 2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 04'th Feb 2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:25am, Tuesday, 13'th Jan 2026
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of “Moderate Buy” by Brokerages
01:44am, Wednesday, 07'th Jan 2026
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 05'th Jan 2026
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year High – Here’s Why
04:36am, Thursday, 25'th Dec 2025
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $21.50 and last traded at $21.48, with a volume of 1371684 sh
Syndax Pharma: Continuing Execution In AML
08:15am, Wednesday, 17'th Dec 2025
Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. SNDX's Revuforj leads in efficacy for AML, with rapid market penetration and a first-move
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
07:00am, Friday, 12'th Dec 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (
Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript
06:47pm, Monday, 08'th Dec 2025
Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript
First Look: IBM nears Confluent deal; Berkshire reshuffle
07:37am, Monday, 08'th Dec 2025
Stock News China's trade surplus tops $1T YTD: China's exports rose 5.9% in November while imports grew 1.9%, pushing the 11âmonth surplus to nearly $1.08 tri
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 03'rd Dec 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
07:00am, Monday, 01'st Dec 2025
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
